Elacestrant(RAD1901)口服SERD治疗ER阳性HER2阴性晚期乳腺癌的I期研究
该I期研究评估了口服选择性雌激素受体降解剂elacestrant在经重度治疗的ER阳性/HER2阴性转移性乳腺癌患者中的安全性、耐受性和抗肿瘤活性,并确定RP2D为400 mg每日一次。研究未观察到剂量限制性毒性,常见不良事件为恶心和高甘油三酯血症等,多为1-2级;在RP2D可评估患者中客观缓解率为19.4%,ESR1突变患者中为33.3%。
要点
- Elacestrant 400 mg每日一次在重度经治ER阳性转移性乳腺癌中安全性可接受。
- RP2D可评估患者客观缓解率19.4%,ESR1突变患者客观缓解率33.3%。
- 临床获益与ESR1突变等位基因丰度下降相关。
核心结论
- Elacestrant 400 mg口服每日一次安全性可接受,在重度经治ER阳性转移性乳腺癌中显示出单药抗肿瘤活性,包括ESR1突变、既往CDK4/6抑制剂和既往SERD治疗患者。
研究设计与样本
- I期研究(RAD1901-005;NCT02338349),采用3+3设计(elacestrant胶囊)确定RP2D,随后在RP2D(400 mg胶囊,后为400 mg片剂)扩展评估安全性和抗肿瘤活性。
- 共入组57例绝经后女性,其中50例接受RP2D(400 mg每日一次);中位年龄63岁,中位既往抗肿瘤治疗线数3线。
主要发现
- RP2D(400 mg片剂,n=24)最常见不良事件为恶心(33.3%)、血甘油三酯升高和血磷降低(各25.0%),大多数不良事件为1-2级。
- RP2D可评估患者(n=31)客观缓解率为19.4%,既往SERD治疗患者为15.0%,既往CDK4/6抑制剂治疗患者为16.7%,ESR1突变患者为33.3%(n=5/15)。
- RP2D患者(n=47)24周临床获益率为42.6%,ESR1突变患者为56.5%(n=23),既往CDK4/6抑制剂治疗患者为30.4%(n=23)。
- Elacestrant临床获益与ESR1突变等位基因丰度下降相关。
关键数值与推荐
- RP2D确定为400 mg每日一次口服。
- RP2D可评估患者客观缓解率19.4%(n=31),ESR1突变患者客观缓解率33.3%(n=5/15)。
- RP2D患者24周临床获益率42.6%(n=47),ESR1突变患者56.5%(n=23),既往CDK4/6抑制剂治疗患者30.4%(n=23)。
临床怎么用
- Elacestrant 400 mg每日一次可作为ER阳性/HER2阴性转移性乳腺癌的后线内分泌治疗选择,尤其对ESR1突变患者。
- 治疗期间需监测恶心和高甘油三酯血症等不良事件,多数为1-2级。
局限性
- 本研究为I期单臂研究,样本量有限,疗效结论需III期随机试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This phase I study (RAD1901-005; NCT02338349) evaluated elacestrant, an investigational oral selective estrogen receptor degrader (SERD), in heavily pretreated women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer, including those with estrogen receptor gene alpha (ESR1) mutation. The primary objective was to determine the maximum tolerated dose and/or recommended phase II dose (RP2D). METHODS: The study consisted of a 3 + 3 design (elacestrant capsules) followed by expansion at RP2D (400-mg capsules, then 400-mg tablets) for the evaluation of safety and antitumor activity. Elacestrant was taken once daily until progression or intolerability. RESULTS: Of 57 postmenopausal women enrolled, 50 received RP2D (400 mg once daily): median age, 63 years; median three prior anticancer therapies, including cyclin-dependent kinase 4,6 inhibitors (CDK4/6i; 52%), SERD (52%), and ESR1 mutation (circulating tumor DNA; 50%). No dose-limiting toxicities occurred; the most common adverse events at RP2D (400-mg tablet; n = 24) were nausea (33.3%) and increased blood triglycerides and decreased blood phosphorus (25.0% each). Most adverse events were grade 1-2 in severity. The objective response rate was 19.4% (n = 31 evaluable patients receiving RP2D), 15.0% in patients with prior SERD, 16.7% in patients with prior CDK4/6i, and 33.3% in patients with ESR1 mutation (n = 5/15). The clinical benefit rate (24-week) was 42.6% overall (n = 47 patients receiving RP2D), 56.5% (n = 23, ESR1 mutation), and 30.4% (n = 23, prior CDK4/6i). Elacestrant clinical benefit was associated with decline in ESR1 mutant allele fraction. CONCLUSION: Elacestrant 400 mg orally once daily has an acceptable safety profile and demonstrated single-agent activity with confirmed partial responses in heavily pretreated patients with estrogen receptor-positive metastatic breast cancer. Notably, responses were observed in patients with ESR1 mutation as well as those with prior CDK4/6i and prior SERD. A phase III trial investigating elacestrant versus standard endocrine therapy is ongoing.
引用
- Bardia A, Kaklamani V, Wilks S, et al. Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer. J Clin Oncol. 2021. PMID: 33513026. doi:10.1200/JCO.20.02272
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。